Background {#Sec1}
==========

Pancreaticoduodenectomy (PD) is a complicated abdominal surgical procedure and postoperative mortality for PD has decreased to 3--5% with improvements in the surgical technique and perioperative management \[[@CR1]--[@CR3]\]. However, the complication rate following PD is still as high as 30--60% \[[@CR4], [@CR5]\]. Hypoalbuminemia (HA) is a risk factor for pancreatic fistula and other complications such as bleeding, intra-abdominal abscess formation, and multiple organ failure, thereby increasing postoperative mortality rate \[[@CR6], [@CR7]\]. Multiple studies have reported that HA may increase the incidence of complications and mortality, prolong ICU admission and hospital stay, and increase the cost of medical resources \[[@CR8], [@CR9]\]. Infusion of exogenous albumin (ALB) was reported to improve clinical outcomes in several studies, although other studies reached the opposite conclusion \[[@CR10]--[@CR14]\]. Despite inconsistent conclusions, clinicians often aim to increase postoperative ALB level to a so-called "safe" range to improve patient condition. However, the cause and effect relationship between HA and postoperative prognosis is still widely disputed. As a challenging abdominal surgical procedure, PD comprises various types of abdominal surgeries including organ resection and digestive tract reconstruction. It is of great clinical significance to investigate the factors that influence postoperative HA and related complications in PD compared with other abdominal operations.

The postoperative ALB level is affected by the recovery process, complications, and daily fluid therapy management strategy, such as the ratio of crystalloid/colloidal fluid. Therefore, this study aimed to explore the factors influencing postoperative HA and assess the relationship between ALB changes and complications after PD. In addition, we aimed to investigate the role of exogenous albumin in the prognosis of patients after PD.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

All subjects have given written informed consent and the study protocol was approved by Ethics Committee of Hunan Provincial People's Hospital, The First Hospital Affiliated with Hunan Normal University (Approval No. 2702, Date 2015-12-04). In this prospective study, 238 consecutive patients who had undergone PD during two-year period between January 2016 and January 2018 in our hospital were initially enrolled. Patients were excluded if they underwent: (1) pancreatogastrostomy reconstruction; (2) Braun anastomosis in digestive tract reconstruction; and (3) total laparoscopic PD and conversion to open procedure, to avoid the interference of additional procedures on patient prognosis. All patients were subdivided into two groups according to the postoperative status of HA: HA group and non-HA group. HA was defined by serum ALB level ≤ 30 g/L until the 14th day after operation independent of the supplementation with exogenous ALB.

Preoperative examination and radiographic assessment {#Sec4}
----------------------------------------------------

Routine blood tests, biochemical examination, measurement of carbohydrate antigen 19--9 (CA19--9), abdominal ultrasound, computed tomography (CT), magnetic resonance imaging (MRI)/magnetic resonance cholangiopancreatography (MRCP), and endoscopic ultrasound (EUS) were performed before operation. Only preoperatively latest examination results were adopted in this study. Routine blood tests, liver and kidney function tests, electrolyte levels, coagulation, and C-reactive protein (CRP) level, amylase levels in blood and drainage, and lipase detection were examined on the 1, 3, 5, 7, 10 and 14 days after operation. Postoperative abdominal ultrasound and/or CT were applied to evaluate ascites routinely.

Operative procedure {#Sec5}
-------------------

Classical PD was performed for all patients. Briefly, after kocherization of the pancreatic head and duodenum, the pancreas was divided anteriorly and to the left of the superior mesenteric vein and portal vein. En bloc removal of each specimen involved distal stomach resection at 10--40% and removal of all of the duodenum, gallbladder, and common bile duct (transected at the cystic duct confluence level) as well as approximately 10--20 cm of the proximal jejunum distal to the ligament of Treitz, with resection of the head, neck, and uncinate process of the pancreas. The scope of lymphadenectomy was dependent on the nature of the lesions and observations on operative exploration. Types of pancreaticojejunostomy reconstruction comprised of duct-to-mucosa end-to-side pancreaticojejunostomy with internal or external stent, invagination pancreaticojejunostomy with internal or external stent, or pancreaticojejunostomy without stent application. The stenting silicone tube could be guided externally through the jejunal loop (external stent) or cut short and left in the jejunal loop (internal stent).

Definition and classification of complications {#Sec6}
----------------------------------------------

Postoperative complications were graded according to the Clavien--Dindo criteria \[[@CR15]\]. Postoperative pancreatic fistula (POPF) was defined by an amylase concentration in the drainage fluid exceeding three times the upper limit of normal value or pancreatic intestinal anastomotic rupture on imaging \[[@CR16]\]. Delayed gastric emptying (DGE) was defined by: 1) nasogastric tube decompression ≥3 days and meeting one of the following standards: a) vomiting after nasogastric tube removal, b) medication needed to improve gastrointestinal motility at 10 days postoperatively, c) replacement of the gastric tube, and d) inability to tolerate a solid diet by 7 days after operation; or 2) nasogastric tube decompression ≥10 days and meeting two of the explained standards \[[@CR17]\]. Postpancreatectomy hemorrhage (PPH) cases were divided into early stage hemorrhage within 24 h after operation and late stage hemorrhage occurring more than 24 h after operation \[[@CR18]\]. Ascites was detected by postoperative abdominal ultrasound or CT after exclusion of pancreatic fistula, biliary fistula, anastomotic fistula, or chylous ascites, and the ascites severity was further graded as mild when the depth of effusion was \< 3 cm or the daily drainage was \< 50 ml, as middle when the depth of effusion was 3--5 cm or the daily drainage was between 50 and 500 ml, and large when the depth of effusion was ≥5 cm or the daily drainage exceeded 500 ml. Hyperbilirubinemia was defined by blood TBIL ≥171.0 μmol/L, postoperative TBIL elevation to ≥171.0 μmol/L in patients with a preoperative TBIL \< 171.0 μmol/L, or postoperative elevation to ≥171.0 μmol/L after transient decline. Infectious complications included incision infection, intra-abdominal abscess, anastomotic fistula, pneumonia, and septicemia \[[@CR19]\].

Postoperative management {#Sec7}
------------------------

All patients received standard care for postoperative management. Somatostatin (3 mg/Q12h) was administered to all patients by transfusion with a micro-infusion pump through postoperative day 7 or extended according to postoperative complications. A gastric tube was routinely placed preoperatively and removed after the recovery of gastrointestinal function. The drainage tube was removed if there was no evidence of biliary fistula or pancreatic fistula. Total parenteral nutrition was used for patients with an inadequate diet and stopped when the patients could tolerate at least half of their oral diet. An exogenous ALB preparation (Baxter Healthcare, Deerfield, USA) was adopted to maintain ALB level \> 30 g/L. The endpoint was short-term analysis of early postoperative results.

Statistical analysis {#Sec8}
--------------------

Measurement data are depicted as median (minimum - maximum). Rates were compared by Pearson *x*^*2*^ test, Fisher's test, or Wilcoxon rank sum test. The medians were compared by the Mann--Whitney *U* test. Binary logistic regression was used for postoperative univariate and multivariate analyses. Canonical correlation analysis was used to evaluate the relationship of postoperative ALB level and infused amount with indicators and complications. A standardized canonical coefficient (SCC) \> 0.5 was considered relevant. All statistical analysis was performed using PASW Statistics software 18.0 (SPSS Inc., Chicago, USA). *P* \< 0.05 was considered significant.

Results {#Sec9}
=======

Patient characteristics {#Sec10}
-----------------------

A total of 238 patients underwent PD between January 2016 and January 2018 in our hospital. Of these, 13 cases with pancreatogastrostomy reconstruction, 15 cases with Braun anastomosis in the digestive tract reconstruction, 43 cases with total laparoscopic PD, and 4 cases that required conversion to laparotomy were excluded. The remaining 163 patients were enrolled in the present study, including 35 cases of lower common bile duct cancer, 49 cases of duodenal papilla carcinoma, 49 cases of pancreatic head carcinoma, 17 cases of periampullary carcinoma, and 13 cases with an inflammatory mass at the head of the pancreas. On the postoperative pathology, 140 cases were confirmed to be adenocarcinoma, 2 cases were adenosquamous carcinoma, 5 cases were mucinous adenocarcinoma, 12 cases involved an inflammatory mass, 2 cases were cystadenocarcinoma, 1 case was sarcoma, and 1 case involved a retention cyst. The ratio of men to women was 1.3:1, and the average patient age was 57.8 years (range, 36--79 years; Table [1](#Tab1){ref-type="table"}). Table 1Analysis of potential factors as predictors of postoperative HAFactorHA(*n* = 61)non-HA(*n* = 102)UnivariateMultivariateOR95% CI*P value*OR95% CI*P value****Patient characteristics*** Gender  Male29621  Female32400.6040.317--1.1490.124 Age (years)^a^59.6 ± 8.556.6 ± 9.71.0361.000--1.0740.051 Weight loss \> 5 kg  Yes16311  No45710.6210.284--1.3570.232BMI(kg/m^2^)^a^21.6 ± 3.121.6 ± 3.31.0000.884--1.1310.996 Diabetes mellitus  No58971  Yes351.0210.235--4.4330.978 Acute pancreatitis  No59981  Yes240.8450.150--4.7570.848 Chronic pancreatitis  No42571  Yes19451.0210.235--4.4330.978 Preoperative biliary drainage  No58941  Yes380.6180.158--2.4270.491 Preoperative ALB usage  No58971  Yes350.2760.046--1.6380.157 Preoperative ALB usage ^a^(g)14.7 ± 4.234.5 ± 9.40.9990.975--1.0230.910 WBC(× 10^9^/L)^a^6.6 ± 2.36.3 ± 2.11.0740.926--1.2470.346 NEUT(×10^9^/L)^a^4.6 ± 2.04.3 ± 1.91.0870.923--1.2800.319 LYMP(×10^9^/L)^a^1.2 ± 0.51.4 ± 0.60.6310.337--1.1820.151 CRP (mg/L) ^a^16.1 ± 5.419.7 ± 7.61.0110.968--1.0560.617 RBC (× 10^12^/L)^a^3.8 ± 0.53.9 ± 0.60.7200.402--1.2900.270 Hb(g/L)^a^116.3 ± 17.6119.8 ± 19.40.9900.973--1.0070.263 HCT(%)^a^33.6 ± 4.936.7 ± 4.60.8630.719--1.0350.112 PLT (×10^9^/L)^a^206.7 ± 90.4224.6 ± 94.60.9980.994--1.0020.247 PT(s)^a^11.5 ± 1.711.3 ± 1.61.0890.891--1.3300.406 APTT(s)^a^28.2 ± 4.727.4 ± 4.91.0320.964--1.1040.371 TT(s)^a^19.8 ± 2.919.4 ± 2.51.0620.937--1.2030.346 INR^a^0.9 ± 0.10.9 ± 0.21.7630.180--7.2280.626 ALT (U/L) ^a^112.3 ± 95.2162.3 ± 78.80.9970.995--1.0000.057 AST (U/L) ^a^96.0 ± 65.1115.6 ± 94.70.9970.993--1.0010.165 ALP (U/L) ^a^509.3 ± 390.1498.4 ± 374.01.0000.999--1.0010.861 TBIL ≥171.1 (μmol/L)  No34761  Yes27262.2141.117--4.3900.0230.9970.267--3.7200.997 TP (g/L) ^a^59.4 ± 2.861.7 ± 6.00.9050.755--1.0840.279 Preoperative ALB ≥35.0 (g/L)  No25261  Yes36760.4800.241--0.9550.0370.4470.210--0.9520.037 GLB (g/L) ^a^25.7 ± 3.524.9 ± 3.71.0620.853--1.3230.588 PA (mg/L) ^a^201.8 ± 95.9187.2 ± 71.71.0020.997--1.0070.366 AMY (U/L) ^a^85.0 ± 59.2145.6 ± 106.30.9960.988--1.0040.347 CA19--9 (U/mL)^a^648.5 ± 133.7622.8 ± 147.21.0001.000--1.0000.941 Site of Lesion  Distal common bile duct1817(16.7)10.262  Duodenal papilla17(27.9)32(31.4)0.4720.193--1.1550.100  Pancreatic head21(34.4)41(40.2)0.5610.234--1.3420.194  Ampullary5(8.2)12(11.8)0.7470.557--1.0030.052***Intra-Operative factors*** Operation time (h) ^a^7.6 ± 1.57.8 ± 1.70.9230.754--1.1290.435 Estimated Blood loss(ml) ^a^591.5 ± 451.2497.4 ± 311.11.0011.000--1.0020.128 pRBC transfusion (U) ^a^1.7 ± 0.61.5 ± 0.51.0810.881--1.3250.455 Plasma transfusion(ml)237.5 ± 80.3132.8 ± 50.91.0021.000--1.0040.0091.0021.000--1.0030.057 Total liquid volume(ml)5829.2 ± 1431.76171.3 ± 1544.21.0001.000--1.0000.275 Ratio of crystal fluid/colloid fluid1.8 ± 0.52.3 ± 0.60.2190.046--1.0400.056 Pancreatic gland texture  Soft36581  Hard25440.6030.322--1.1290.114 Pancreatic duct diameter \> 0.3 cm  No272511  Yes34770.4250.215--0.8390.0140.8190.369--1.8150.622 PJ-R Type  IPJ (external stenting)498110.219  DMPJ (external stenting)02------  DMPJ (internal stenting)4141.1890.449--3.1520.728  IPJ (no stenting)545.8330.953--7.7170.056  IPJ (internal stenting)311.4600.914--2.3300.113 Combined portal vein resection  No601001  Yes121.1800.105--3.2960.893 Resectional margin status  R0^b^539110.697  R1551.6920.468--6.1240.423  R2361.0460.559--1.9560.889***Pathological characteristics and postoperative complications*** Pathology  Adenocarcinoma59(96.7)85(83.3)10.949  Mucinous adenocarcinoma0(0)5(4.9)------  Inflammation mass2100.7540.565--1.0050.054  Sarcoma01------  Retention cyst01------ Tumor Differentiation  Inflammation21110.570  High26450.9000.356--2.2740.824  Moderate23271.0330.592--3.9740.379  Poor10191.1670.758--1.7970.484 Clavien-Dindo grade  0286110.26210.173  I11250.4720.193--1.1550.1000.6200.105--3.6560.597  II1260.5610.234--1.3420.1941.1270.179---7.0850.899  IIIa253.7650.897--9.2960.0671.5820.316--7.9270.577  IIIb243.3511.641--6.8450.0014.3171.479--12.6020.007  IVa20------------  IVb00------------  V411.6541.186--2.3060.0031.6051.097--2.3490.015*Abbreviations: OR odds ratio, BMI* body mass index, *TBIL* total bilirubin, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *ALP* alkaline phosphatase, *TP* total protein, *GLB* globulin, *ALB* albumin, *PA* prealbumin, *AMY* amylase, *CRP* C-reactive protein, *RBC* red blood cell count, *WBC* white blood cell count, *NEUT* neutrophil count, *LYMP* lymphocyte count, *Hb* hemoglobin, *PLT* platelet count, *HCT* hematocrit, *PT* prothrombin time, *APTT* activated partial thromboplastin time, *TT* thrombin time, *INR* international normalized ratio, *CA19--9* carbohydrate antigen 19--9, *pRBC* packed red blood cell, *PJ-R* pancreaticojejunostomy reconstruction, *DMPJ* duct-to-mucosa end-to-side pancreaticojejunostomy, *IPJ* invagination pancreaticojejunostomy^a^ expressed as Mean ± SD;^b^The resectional margin status in non-malignant disease was classified and analyzed as R0

Postoperative complications {#Sec11}
---------------------------

A total of 89 (54.6%) cases had no complications. According to classification based on the Clavien-- Dindo criteria, the percentages of all patients who experienced grade I to grade V complications were grade I 22.1% (36/163), grade II 11.0% (18/163), grade IIIa 4.3% (7/163), grade IIIb 3.7% (6/163), grade IVa 1.2% (2/163), grade IVb 0% (0/163), and grade V 3.1% (5/163), respectively. The 30-day in-hospital mortality was two cases in HA group and one case in non-HA group, and 60-day in-hospital mortality was three cases in HA group and two cases in non-HA group, showing no significant difference.

The most common complication was ascites (37.4%), followed by infection (30.1%), pancreatic fistula (18.4%), and postoperative upper gastrointestinal tract hemorrhage (6.1%). Five patients presented with early intraperitoneal hemorrhage, of which two cases underwent reoperation and three received conservative treatment, two cases were cured after conservative treatment, and one died due to liver and kidney dysfunction. Nine cases experienced late intraperitoneal hemorrhage, of which three cases received laparotomy after hemostatic failure, two cases underwent interventional embolization treatment, and four cases were treated with double-catheter irrigation and local application of hemostatic drugs.

The incidence of upper gastrointestinal hemorrhage was 6.1% (10/163), including one case that experienced early upper gastrointestinal bleeding within 12 h and was treated with hemostatic drugs and nine cases with late bleeding within 3 \~ 23 days postoperatively that resolved after conservative treatment. Five patients presented with biliary fistula (3.1%), including one case of both pancreatic fistula and late intraperitoneal hemorrhage that was treated by reoperation. The percentages of patients who experienced DGE of grades B and C were 1.8% (3/163) and 1.2% (2/163), respectively, and hyperbilirubinemia affected 6.13% (10/163) of the patients.

Most complications were evaluated as grade I, including incision site infection and urinary tract infection. Intra-abdominal abscess formation (1.8%) was the most common type of infection among cases with grade II complications.

Factors influencing HA after PD {#Sec12}
-------------------------------

Univariate analysis showed that the following five factors were associated with postoperative HA: preoperative TBIL ≥171.1 μmol/L, preoperative ALB ≥35.0 g/L, classification of complications, main pancreatic duct inner diameter \> 0.3 cm, and intraoperative plasma transfusion (Table [1](#Tab1){ref-type="table"}). Multivariate analysis showed that preoperative ALB ≥35.0 g/L and the complication grade were the factors significantly influencing HA after PD (Table [1](#Tab1){ref-type="table"}).

Correlations of preoperative ALB level and ALB infusion with various indicators {#Sec13}
-------------------------------------------------------------------------------

As shown in Table [2](#Tab2){ref-type="table"}, liver function, inflammatory reaction index, coagulation, renal function and electrolyte index, postoperative complications, digestive tract anastomotic leakage, postoperative RBC and plasma transfusion, ascites, and diarrhea and somatostatin application exhibited correlation with ALB level and ALB infusion amount. No coagulation index was relevant with ALB level and ALB infusion amount. Surgical treatment of complication, early and late postoperative intraperitoneal hemorrhage were significantly correlated with HA. RBC and plasma transfusion may not affect serum ALB level. High request of RBC transfusion, such as severe complication, may generate the clinical circumstance of ALB infusion to correct HA. ALB level showed no correlation with ascites formation and volume. ALB infusion amount exhibited weak positive correlation with ascites, and weak negative correlation with positive germiculture in abdominal drainage. Somatostatin application and diarrhea after operation showed no correlation. Table 2Correlation analysis of postoperative ALB level, infused exogenous ALB and various indicatorsItemrWilk'sχ^2^DF*P* valueUVLiver function0.9990.0011815.22526.0000.0000.414 × ALB level+1.082 × ALB infusion amount−0.001 × ALT + 0.000 × AST + 0.003 × ALP -- 1.697 × TP+  1.160 × GLB − 0.006 × PA + 0.004 × TBILBlood routine0.6780.467202.34222.0000.000−0.652 × ALB level+0.547 × ALB infusion amount− 0.385 × RBC + 0.176 × Hb -- 0.137 × HCT--3.084 × WBC − 3.327 × NEUT--0.001 × LYMP − 0.475 × PLT--0.765 × CRPCoagulation0.5310.59863.71514.0000.0001.044 × ALB level +0.111 × ALB infusion amount0.218 × PT + 0.093 × APTT + 0.091 × TT + 0.347 × INRRenal function and electrolyte0.9970.00237.22418.0000.0050.487 × ALB level--0.675 × ALB infusion amount0.284 × Na^+^+ 0.056 × K^+^+ 0.248 × CL^−^--0.025 × Ca^2+^+ 0.220 × Mg^2+^−0.296 × P-- 1.737 × Urea--2.597 × CrBlood and drainageamylase and lipase0.5620.67111.7768.0000.162----Clavien-DindoGrade, PIH and reoperation0.2890.90523.53210.0000.0090.323 × ALB level +1.092 × ALB infusion amount−0.441 × Clavien-Dindo grade + 1.026 × reoperation +1.298 × EPIH + 0.993 × LPIHAnastomotic leakage0.4220.78352.83510.0000.000−0.408 × ALB level +0.754 × ALB infusion amount-- 0.180 × biliary fistula+ 1.219 × PF+ 0.540 × PF classification− 0.162 × infectious complicationsHyperbilirubinemia0.1250.9843.6112.0000.164----Gastrointestinalhemorrhage0.4170.8253.9404.0000.414----Postoperative pRBC and plasma transfusion0.1760.96211.1834.0000.025−0.527 × ALB level--1.074 × ALB infusion amount−0.801 × pRBCtransfusion− 0.372 × plasma transfusionAscites, pleural effusion and intraabdominal drainage germiculture0.4130.79949.6098.0000.000−0.122 × ALB level+0.944 × ALB infusion amount0.575 × ascites + 0.372 × ascites severity+ 0.440 × pleural effusion− 0.651 × positive germiculture − 0.107 × positive fungus cultureDiarrhea, somatostatin analogs use0.4300.79512.7404.0000.013−0.311) × ALB level --0.996 × ALB infusion amount−0.441 × diarrhea− 0.002 × somatostatin analogs use*Abbreviations: PIH* postoperative intraperitoneal hemorrhage, *EPIH* early postoperative intraperitoneal hemorrhage, *LPIH* late postoperative intraperitoneal hemorrhage, *PF* pancreatic fistula

Comparison of postoperative parameters between HA and non-HA groups {#Sec14}
-------------------------------------------------------------------

No significant difference was observed in the rates of complications between the HA and non-HA groups (Table [3](#Tab3){ref-type="table"}). Moreover, no differences were observed in the total amount of ALB infused (*P* = 0.186), ALB infusion frequency (*P* = 0.365), or postoperative 30, 60-day fatality rate (*P* = 0.557, 0.066, respectively) between the two groups. The classes of complications showed significant difference between the two groups (*P* = 0.020). Table 3Comparison of postoperative parameters between HA and non-HA groupsParametersHA(*n* = 61)non-HA(*n* = 102)*P* value ^*a*^EPPH320.360EPPH treatment1.000 Non-surgical therapy21 Reoperation11LPPH450.729LPPH treatment Conservation130.539 Intervention11 Surgery21POPF12180.747POPF grade0.076^*b*^ A614 B23 C41Biliary fistula140.651DGE Grade C231.000Hyperbilirubinemia461.000Infection complications20290.557 ^*c*^Infection site Incision15150.079 ^*c*^ Lung10 Intra-abdominal414Ascites26350.289^*c*^Ascites severity Mild14250.157^*c*^ Middle1210Postoperative delirium310.148Cardiovascular events100.374Liver dysfunction200.139Upper gastrointestinal hemorrhage550.503Lower gastrointestinal hemorrhage100.374Multiorgan dysfunction210.557Clavien-Dindo classification0.020^*b*^ 02861 I1125 II126 IIIa25 IIIb24 IVa20 IVb00 V41Reoperation241.000Postoperative ALB infusion dosage(g) \*169.0 ± 126.1115.6 ± 87.90.186 ^*d*^Postoperative ALB infusion frequency\*10.7 ± 6.95.81 ± 4.00.365^*d*^Somatostatin application (day) \*9.3 ± 4.210.1 ± 3.80.215 ^*d*^Postoperative pRBC transfusion(U) \*4.3 ± 3.14.0 ± 1.90.003 ^*d*^Postoperative plasma transfusion (ml) \*869.0 ± 633.8545.9 ± 373.10.086 ^*d*^Hospital stay (days) \*30.0 ± 13.629.2 ± 13.40.658 ^*d*^30-day Mortality210.55760-day Mortality410.066*a: Fisher's exact test; b: Wilcoxon rank sum test; c: Pearson x*^*2*^*test; d: Mann-Whitney U testAbbreviations: EPPH* early postpancreatectomy hemorrhage, LPPH Late postpancreatectomy hemorrhage\* expressed as Mean ± SD

Discussion {#Sec15}
==========

In this study, we analyzed the factors influencing HA after PD and the effects of HA on short-term prognosis. Multivariate analysis showed that preoperative ALB ≥35.0 g/L and the classification of postoperative complications significantly affected the occurrence of HA after PD, but the underlying mechanism is still elusive. We postulate that ALB level may indicate inflammation status in the body which may affect postoperative HA, but further studies are needed to confirm it.

Correlation analysis showed that postoperative ALB level was only negatively correlated with WBC and neutrophil counts. The amount of exogenous ALB infused postoperatively was negatively correlated with TP but positively correlated with BUN, Cr, complications requiring surgical intervention, early intraperitoneal hemorrhage, late intraperitoneal hemorrhage and pancreatic fistula. Importantly, the incidences of complications and the 30-day mortality rates did not differ significantly between HA group and non-HA group.

About 20--40% of patients present with HA after selected operations \[[@CR20]\]. Exogenous ALB infusion may correct postoperative HA and maintain intravascular colloid osmotic pressure. However, the endothelial glycocalyx (EG) layer plays a role in intra- and extracellular liquid exchange, reabsorption of interstitial fluid may not occur even if exogenous ALB is infused to improve plasma colloid osmotic pressure \[[@CR21]\]. In addition, although ALB is a key component of the EG layer, only 25% of physiological concentration of ALB can maintain the complete EG layer, and EG layer remains functional even with an ALB level of 10 g/L \[[@CR22]\]. Thus, exogenous ALB infusion is not recommended to improve and maintain the function of the EG layer.

ALB level after PD and infusion of exogenous ALB exhibited no relationship with HCT in this study, indicating that hemodilution was not the main reason for HA, consistent with previous report \[[@CR20]\]. The integrity and function of the EG layer suffer damage during inflammatory response \[[@CR23]\]. Excessive inflammation leads to the release of many inflammatory mediators and increased number of blood leukocytes, especially neutrophils, contributing to EG layer barrier dysfunction, leukocyte adhesion to the vascular wall and increased vascular permeability \[[@CR24]\].

This study revealed that postoperative ALB level negatively correlated with postoperative inflammation indexes, such as WBC count, neutrophil absolute value, and CRP level. The correlation of CRP with postoperative ALB level was lower than that of the WBC and neutrophil counts, suggesting that WBC and neutrophils, especially neutrophils, have specific roles in the ALB decline after PD, probably via damage to the EG layer. We speculated that the surgery itself, as the initial stimulus of inflammation, led to an increase in the WBC count, especially in neutrophils. The release, activation and dynamic changes of different subgroups of neutrophils contributed to the damage and subsequent dysfunction of the EG layer. This may explain why infusion of exogenous ALB cannot reliably improve HA in some patients and even correcting ALB level \> 30 g/L does not effectively prevent serious complications. Furthermore, such damage and functional loss of the EG layer may not be resolved while inflammation subsides during recovery, as reflected by a decrease in the neutrophil count, because serum ALB level slowly returns to the normal range over a relatively long time after the operation.

Anastomotic fistula after PD, including bile leakage, pancreatic leakage, and intra-abdominal abscess formation, is the most serious complication that significantly increases postoperative mortality, and may become aggravated as late as the 8-12th day \[[@CR25]\]. This study demonstrated that a reduction in postoperative ALB may not affect the occurrence of pancreatic fistula. Moreover, infusion of exogenous ALB could not prevent the occurrence of pancreatic fistula. However, exogenous ALB infusion was positively correlated with surgical treatment of postoperative complications and postoperative intraperitoneal hemorrhage, especially the early postoperative intraperitoneal hemorrhage. Early hemorrhage after PD can be caused by the operative technique or coagulation dysfunction, which usually requires abdominal laparotomy to stop the bleeding \[[@CR1]\]. For the patients who underwent reoperation, two operations in a short period induced excessive inflammation, leading to ALB decrease. In this case, the clinician may use exogenous ALB to correct HA. However, late postoperative bleeding usually occurs in 1--3 weeks after surgery. The cause of this complication is complex and may be related to peripancreatic blood vessel corrosion secondary to pancreatic leakage, aneurysm formation, or ulceration of anastomotic site \[[@CR26]\]. Generally, postoperative bleeding can be stopped upon interventional therapy or endoscopic treatment under local anesthesia. Our results suggest that postoperative RBC or plasma transfusion did not improve ALB level.

Based on our results, the strategy for correcting HA after PD is to block or rapidly end the acute phase of the inflammatory response and protect or restore the EG layer, although the clinical benefit of this approach is questionable. In addition, careful attention to perioperative nutritional support can help patients pass through the acute stress reaction period, even though parenteral nutrition has been shown to seldom correct ALB concentration to normal level \[[@CR27]\].

There are several limitations in this study. First, PD procedures were performed by different physicians, and thus the amounts of fluid infused daily and the ratio of crystal and colloid varied. The impact of such differences on the occurrence of postoperative complications is difficult to evaluate. Second, exogenous ALB preparation used in this study was 20% concentration, and the impact of other concentrations of ALB on HA after PD remains unclear. Third, the variety of diagnoses may contribute to possible bias in our conclusion. Fourth, we only evaluated short-term outcomes of patients after PD and exogenous ALB infusion. Fifth, the sample size is not big enough. Further multi-center randomized prospective studies with long-term follow-up are needed.

Conclusions {#Sec16}
===========

Our study provides further evidence that HA should not be considered as an indicator but rather a result of poor prognosis. WBC, especially neutrophils, exhibit unique role in reducing postoperative ALB level. Infusion of exogenous ALB to maintain ALB \> 30 g/L has no clinical benefit for patients after PD.

ALB

:   Albumin

HA

:   Hypoalbuminemia

PD

:   Pancreaticoduodenectomy
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